Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy Leukemia (2009) Imatinib mesylate (IM) at 400 mg daily has now become the standard of care for newly diagnosed Philadelphia-positive (Ph þ ) chronic phase-chronic myelogenous leukaemia (CP-CML), and a vast majority of patients show optimal responses translating into high rates of long-term survival. Despite these unprecedented results, up to 23% of patients are reported to discontinue IM treatment, because of an insufficient therapeutic effect. 1 Although a lot of progress has been made for patients showing IM resistance, there is no consensus regarding the management of patients with suboptimal responses. Current options in this setting include continuation of IM at the initial dose, dose escalation of the drug or enrolment into investigational trials. In this study, we retrospectively analyzed the impact of IM dose escalation in 23 newly diagnosed CP-CML patients treated with first-line IM, which showed cytogenetic or primary molecular suboptimal responses as defined by Baccarani et al. 2 It is not clear to date whether these patients need to be considered as primary-resistant to IM or solely insufficient responders for pharmacological reasons, excluding non-compliance.
In suboptimal cytogenetic responders (n ¼ 10), the median duration of IM 400 was 12 months (6-15) and the median follow-up on IM after dose increase was 27 months (10-79) ( Table 1) . We found that IM dose escalation was highly efficient in this setting, leading to a 100% rate of complete cytogenetic response (CCyR: 0% Ph þ ) after a median time of 4 months (3-13), that from first intake of IM being 17 months (12-20). All patients maintained a stable CCyR while on IM, with a median follow-up after CCyR achievement of 20 months (6-68). Although we cannot completely rule out that some patients may have gained CCyR upon continuation of IM as initially prescribed, our results favourably compared with those derived from the International Randomized Study of Interferon versus STI571 (IRIS) trial, in which the probability of a delayed CCyR in the absence of any therapeutic change was reported in only 46-57% of the patients after 24 months on IM 400. 3 In addition, overall survival and progression-free survival remained similar in patients with a delayed CCyR when compared with patients with CCyR obtained within the first 12 months of treatment.
None of the suboptimal cytogenetic responders in our series progressed to advanced phases of CML within a median observation timeframe of 41 months (18-88). In contrast, the rate of progression-free survival at 24 months was estimated to be between 68 and 88% in suboptimal cytogenetic responders remaining on IM 400 in the IRIS trial. 4 At the time of CCyR documentation, molecular assessments for residual disease showed a median peripheral blood BCR-ABL % (IS) of 0.398 (0.033-2) (Figure 1a) . A significant decline in BCR-ABL transcripts was observed during the first 6 months following CCyR, with a median BCR-ABL % (IS) ratio at 6 months of 0.058 (0.014-0.396), whereas there was no significant change in transcript levels at later time points (Figure 1a) . Importantly, increasing the dose of IM was accompanied by a remarkably high rate of major molecular response (MMR: BCR-ABL % (IS) p0.1). Nine out of 10 patients (90%) indeed obtained a MMR at least once (Figure 1b) . The median time from CCyR to MMR was 4 months (0-15), that from IM dose escalation was 6 months (3-28) and that from the onset of IM treatment was 20 months (12-34). MMR was sustained in 6/9 patients with a median follow-up after MMR of 22 months . One patient showed a molecular response lightly fluctuating from major to less than major over a period of 62 months. MMR was of short duration in one patient who returned to IM 400 due to intolerance to the 800 mg daily dose and in another patient in whom poor compliance to IM 600 was suspected. Interestingly, we found that before dose increase, 7/10 suboptimal cytogenetic responders with an available mutational analysis (performed by polymerase chain reaction (PCR) and direct sequencing) retained a nonmutated BCR-ABL, in line with a recent report from Soverini et al. 5 who suggested that BCR-ABL mutations were not a predominant mechanism of suboptimal responses in first-line IM-treated patients. Furthermore, 3/10 patients in whom IM trough plasma levels were measured showed low IM concentrations and CCyR achievement upon IM dose escalation was associated with a substantial rise in trough plasma levels of the drug (Table 1) . Therefore, although our cohort remains limited, it is conceivable that these patients show an insufficient response to IM 400 mainly because of pharmacological problems related to absorption, drug interaction, metabolism or IM cellular influx/efflux pumps activity or polymorphisms, rather than initiating a true resistance to IM. Our hypothesis is supported by three former studies. Firstly, Picard et al. 6 observed that patients lacking CCyR at 12 months displayed lower trough plasma IM levels than those with CCyR at the same time point. Second, Wang et al. 7 showed that low levels of expression of OCT-1(Organic cation transporter), an organic cation transporter responsible for IM cellular uptake, was associated with a lower probability of CCyR; unfortunately, we could not verify the OCT-1 status at diagnosis in our cohort. Third, White et al.
8 Table 1 Characteristics of CP-CML patients with primary suboptimal cytogenetic and molecular responses to IM at 400 mg daily Cytogenetic analyses were performed every 3-6 months until complete cytogenetic response (CCyR) was obtained and at least 20 metaphases from bone marrow cells were studied. Molecular responses were assessed at each center at 3-6-month intervals on blood cells by real-time quantitative polymerase chain reaction (PCR). c Suboptimal cytogenetic responders with minimal or minor CyR (96-66% Ph+ and 65-36% Ph+, respectively) at 6 months were treated with IM at a starting dose of 400 mg daily for at least 6 months up to o12 months. Those with a partial CyR (35-1% Ph+) at 12 months were treated with IM at a starting dose of 400 mg daily for at least 12 months up to o18 months. Suboptimal molecular responders were treated with IM at a starting dose of 400 mg daily for at least 18 months.
d IM trough plasma concentrations were determined 21-27 h after the last IM dose administration by high-performance liquid chromatography coupled to electrospray ionization tandem mass spectrometry.
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reported an increased risk of suboptimal responses in patients with low OCT-1 activity receiving IM at less than 600 mg daily. Subsequently, a rapid IM dose escalation to 600-800 mg daily represents a reasonable option to propose to cytogenetic suboptimal responders CP-CML patients, in order to avoid further disease progression. In primary suboptimal molecular responders (n ¼ 13), the dose of IM was increased after a median duration of exposure to initial IM 400 of 27 months (21-58) ( Table 1 ). The median duration of IM treatment after dose escalation of the drug was 24 months (5-51). No spontaneous decline in the leukaemic burden had occurred within 12 months before IM dose escalation (not shown). Among 8/13 patients with mutational analysis, only one harboured a BCR-ABL mutation (M244V). At the time of IM dose escalation, monitoring of the residual disease showed a median BCR-ABL % (IS) ratio of 0.784 (0.25-3.16) (Figure 1c) . A significant decrease in BCR-ABL transcripts occurred during the following 6 months, with a median BCR-ABL % (IS) at 6 months of 0.243 (0.02-1.2), but not at later time points (Figure 1c) . Intensification of IM therapy led to a MMR on at least once in 5/13 patients (38%) after a median duration of high-dose IM treatment of 11 months (3-25) (Figure 1b) . MMR remained stable in four patients over a median observation time of 18 months (7-26). The patient harbouring an M244V mutation prior to dose escalation of IM showed a molecular response lightly fluctuating between major and less than major over a period of 23 months. Comparing primary suboptimal molecular responders reaching MMR and those failing to do so did not reveal significant differences in terms of demography (except for age), disease characteristics, duration of initial and high-dose IM treatment and IM dose issue (data not shown). There was only a trend toward higher BCR-ABL transcripts levels at dose escalation of IM in patients who did not reach MMR. The emergence of a BCR-ABL kinase domain mutation was a rare event, which was thereby not likely to account for the differential effect of dose escalation on the residual disease among patients. Lastly, dose escalation of IM in patients who failed to obtain MMR increased trough drug levels above the so-called therapeutic threshold of 1000 ng/ml, 6 with median concentrations before and after dose increase of 451 (325-1940) and 1422 ng/ml (988-2219), respectively (P ¼ 0.012) ( Table 1) . Whether this threshold is satisfactory in all patients remains questionable. Another explanation may relate to the differential functional activity of OCT-1 among primary suboptimal molecular responders. White et al. 8 indeed found that in patients with insufficient molecular responses, the impact of IM dose escalation on the residual leukaemic burden was dependent on OCT-1 activity: IM dose escalation had no effect in high OCT-1 activity patients ,whereas patients with low OCT-1 activity achieved satisfactory molecular responses. Thus, we could hypothesize that primary suboptimal molecular responders to IM 400 might represent a heterogeneous group of patients: some might respond well to IM dose-increase because of insufficient plasmatic and/or intracellular IM levels, whereas the majority might show a more intrinsic resistance of the residual leukaemic burden, which is likely to benefit from different therapeutic strategies. These last statements rely on a small cohort of patients and our hypothesis should be confirmed in a randomized trial. In conclusion, IM dose escalation represents a valuable option leading, in a vast majority of patients, to optimal cytogenetic and molecular responses in patients with suboptimal cytogenetic responses to frontline IM 400. In patients with primary suboptimal molecular responses, this strategy seems to be less effective and the potential of second-generation tyrosine kinase inhibitors or combination strategies should be investigated to prevent overt resistance. Eicosanoid products of the cyclooxygenase (COX) and lipoxygenase pathways of AA are important mediators of malignant proliferation. 3 Deregulated PLA 2 activity contributes to the pathogenesis of several malignancies including prostate cancer, ovarian carcinoma and colorectal adenocarcinoma. 1, 2 The COX and lipoxygenase pathways of AA have been recently documented on immature leukemic blasts of patients with acute myeloid (AML) and acute lymphoid (ALL) leukemia. 4, 5 Thus, freshly isolated AML and ALL blasts express COX-1, produce the AA metabolite prostaglandin E 2 , express functional EP 2 receptors and increase their growth in response to exogenously added prostaglandin E 2 . The World Health Organization has proposed a classification system that divides AML into several broad groups: AML with genetic abnormalities, AML with multilineage dysplasia, AML related to earlier chemotherapy or radiation and AML not otherwise specified. The latter group contains a subgroup, AML without maturation, which consisted of the weaker immature blast group. In view of the potentially important oncogenic action of PLA 2 in leukemic proliferation, quantitative PCR was used to determine the PLA 2 mRNAs that were expressed in AML blasts without maturation and ALL blasts.
Blood samples recovered on EDTA were obtained from twenty-one AML patients and ten B-ALL patients at diagnosis according to the Helsinki recommendations. AML patients consisted in a homogeneous group of patients with blasts without signs of maturation and no genetic abnormality. Blood
